John Kelly
Analyst · William Blair. Please go ahead
Thank you, Mark, and good afternoon, everyone. Before we begin, please note that I will be discussing non-GAAP financial measures, such as EBITDA, adjusted EBITDA, adjusted net income, adjusted EPS and free cash flow. Our press release, 10-K and Investor Relations page on the Huron website have reconciliations of these non-GAAP measures to the most comparable GAAP measures, along with the discussion of why management uses these non-GAAP measures and why management believes they provide useful information to investors regarding our financial condition and operating results. Also, unless otherwise stated, my comments today are all on a continuing operations basis. Also, during the fourth quarter, we completed the divestiture of our Life Sciences business, which closed at the beginning of November, and is included in our fourth quarter results as part of the Business Advisory segment through the date of divestiture. We closed our acquisition of Whiteboard Higher Education on December 1. Whiteboard is included in our fourth quarter financial results within the Education segment from the date of acquisition. Our recent acquisition of Perception Health closed on December 31, and as such, is not included in our fourth quarter results. The acquisitions of Whiteboard and Perception Health strengthen our deep industry expertise in the education and healthcare sectors, respectively, while broadening our capabilities in student search, data and analytics as we expand our offerings to serve our core end markets. Now let me walk you through some of the key financial results for the quarter. Revenues for the fourth quarter of 2021 were a record of $248.3 million, up 25.2% from $198.3 million in the same quarter of 2020. The increase in revenues in the quarter was driven by strong growth across all three operating segments. For full year 2021, revenue was $905.6 million, up 7.3% from $844.1 million in 2020. Similar to the quarter results, these full year results were our highest revenue to date and reflect growth in all three segments and increased demand for our services across industries following the initial impact of the pandemic. Net income was $31.1 million or $1.45 per diluted share in the fourth quarter of 2021, compared to a net loss of $6.1 million or $0.28 per diluted share in the fourth quarter of 2020. The fourth quarter of 2021 included a $23.7 million gain net of tax related to the sale of our Life Sciences business. The fourth quarter of 2020 included the impact of restructuring and lease impairment charges of $13.9 million net of tax, taken to reduce our operating costs to address the impact of the pandemic on our business. For full year 2021, net income was $63 million or $2.89 per diluted share. This compares to a net loss of $23.7 million or $1.08 per diluted share in 2020. 2020 included the pretax goodwill impairment charge of $59.8 million taken in the first quarter. Our effective income tax rate in the fourth quarter of 2021 was 24.5%. On a full year basis, our effective income tax rate for 2021 was 21.3%, which is more favorable than the statutory rate, inclusive of state income taxes, primarily due to tax benefits related to the CARES Act, the positive impact of certain federal tax credits and a discrete tax benefit recognized during the second quarter of 2021 related to electing the global intangible low taxed income, or GILTI, high-tax exclusion retroactively for the 2018 tax year. Adjusted EBITDA was $29.3 million in Q4 2021 or 11.8% of revenues compared to $17.1 million in Q4 2020 or 8.6% of revenues. For full year 2021, adjusted EBITDA as a percentage of revenues increased to 10.8% compared to 10.3% in 2020. Adjusted non-GAAP net income was $17.2 million or $0.80 per diluted share in the fourth quarter of 2021, compared to $10.2 million or $0.45 per diluted share in the fourth quarter of 2020. For the full year, 2021 adjusted non-GAAP net income was $56.9 million or $2.61 per share compared with $47.9 million or $2.15 per share in 2020. Now, I will make a few comments about the performance of each of our operating segments. The Healthcare segment generated 42% of total company revenues during the fourth quarter of 2021 and posted revenues of $103.7 million, up $18.6 million or 21.8% from the fourth quarter of 2020. The increase in revenue reflects the strength of demand for our performance improvement-related offerings following the initial impact of the COVID-19 pandemic on our business. On a full year basis, Healthcare revenue increased 6.8%. Performance-based fees for the full year 2021 were $73.4 million compared to $69.3 million in 2020. Operating income margin for Healthcare was 24.7% for Q4 2021 compared to 28.3% for the same quarter in 2020. The quarter-over-quarter decline in margin was primarily due to an increase in performance bonus expense for our revenue-generating professionals as a percentage of revenues, partially offset by the decrease in restructuring charges taken in the fourth quarter of 2020. On a full year basis, operating margin was 27.5% compared to 26.9% in 2020. The Business Advisory segment generated 31% of total company revenues during the fourth quarter of 2021 and posted revenues of $77.9 million, up $12 million or 18.2% from the fourth quarter of 2020. Revenues for the fourth quarter of 2021 include the inorganic contributions of $2.4 million from our acquisitions of ForceIQ and Unico Solution. The quarter-over-quarter increase in revenue was primarily attributable to strong demand for our financial advisory, strategy and digital offerings. On a full year basis, the Business Advisory segment revenues were $291.7 million and grew 9.1% year-over-year, driven by strong demand for our digital and strategy offerings. The operating income margin for the Business Advisory segment was 14.1% for Q4 2021, compared to 16.3% for the same quarter in 2020. The quarter-over-quarter decline in margin was primarily due to restructuring charges related to the divestiture of our Life Sciences business during the quarter. The Life Sciences restructuring charges had an approximate 800 basis point impact on Business Advisory segment margin during the quarter. On a full year basis, operating margin was 16.5% compared to 18% in 2020. The fourth quarter of Life Sciences restructuring charges had a 225 basis point impact on full year Business Advisory segment margins. The Education segment generated 27% of total company revenues during the fourth quarter of 2021 and posted record revenues of $66.7 million, up $19.4 million or 41% from the fourth quarter of 2020, which was our low point for this practice during the pandemic. Revenues for the fourth quarter of 2021 included $600,000 from our acquisition of Whiteboard. This increase in revenue reflects the strength of demand for our services across the segment, including our research, strategy and operations, student and digital offerings. On a full year basis, Education segment revenues grew 5.9% year-over-year, driven by strong demand for our research, strategy and operations and student offerings. The operating income margin for Education was 23.3% for Q4 2021, compared to 12.1% for the same quarter in 2020. The quarter-over-quarter increase in margin was primarily due to our revenue growth as well as a decrease in restructuring charges, partially offset by an increase in contractor expense as a percentage of revenues. On a full year basis, operating margin was 22.3% compared to 21.3% in 2020. Other corporate expenses not allocated at the segment level were $36.8 million in Q4 2021, compared with $47.4 million in Q4 2020. The fourth quarter of 2021 included $1.6 million of expense related to the increase in the liability of our deferred compensation plan, which is fully offset by the corresponding gain recorded as other income and the value of the assets used to fund this plan as well as $1.8 million in restructuring charges. The fourth quarter of 2020 included $3.1 million of expense related to the deferred compensation plan and $14.5 million of restructuring expense. Adjusting for the impact of the deferred compensation plan and restructuring charges, year-over-year, corporate expenses increased by $3.6 million for the fourth quarter of 2021. This increase reflects increases in performance bonus expense and salaries and related expenses for our support personnel as well as an increase in professional fees related to M&A activity during the quarter. On a full year basis, corporate expenses not allocated at the segment level, increased 5.5% over 2020 when adjusting for the impact of the deferred compensation plan and restructuring charges. This increase reflects increases in salaries and related expenses, performance bonus expense, retention bonuses for our support personnel and increases in professional fees related to M&A activity in software and data hosting expenses, all partially offset by decreases in share-based compensation expense for our support personnel and practice administration and meetings expenses. Now, turning to the balance sheet and cash flows, DSO came in at 69 days for the fourth quarter of 2021, compared to 76 days for the third quarter of 2021 and 52 days for the fourth quarter of 2020. The increase in cash flow and decrease in DSO during the fourth quarter when compared to the third quarter reflects the collection of working capital on certain larger healthcare and education projects during the quarter in accordance with contractual payment schedules. The increase in DSO compared to the fourth quarter of 2020 reflects several advanced payments by clients and relatively fewer large contracts with extended payment terms in the fourth quarter of last year. We expect DSO to normalize to between 60 and 65 days in 2022. Total debt included the $230 million in senior bank debt and a $3 million promissory note for total debt of $233 million. We finished the year with cash of $21 million for net debt of $212 million. This was a $40 million decrease compared to Q3 2021. Our leverage ratio as defined in our senior bank agreement was approximately 1.7x adjusted EBITDA as of December 31, 2021, compared to 1.9x adjusted EBITDA as of December 31, 2020. We achieved this leverage ratio of 1.7x while deploying $64.6 million to repurchase shares, approximately 1.3 million shares and $45 million in strategic tuck-in acquisitions during 2021. From November of 2020, when our Board of Directors authorized $100 million for share repurchases through the date of this call, we have repurchased approximately 1.9 million shares for a total of $93 million. Cash flow from operations for 2021 was $18 million, and we used $16 million of our cash to invest in capital expenditures, resulting in free cash flow of $2 million. Adjusting for the impact of our Life Sciences divestiture by excluding transaction-related employee and third-party costs as well as tax payments and net working capital adjustments, our free cash flow for the year was approximately $21 million. This free cash flow yield is lower than our historical amounts reflecting the record low DSO as of December 31, 2020 and the pull forward of certain cash receipts into the fourth quarter of 2020. The repayment in 2021 of $12 million of 2020 FICA deferrals under the CARES Act and a DSO higher than our target of 60 days as of December 31, 2021, due to the impact of certain larger healthcare and education projects with extended contractual payment terms. We expect our free cash flow yield to normalize to historical levels in 2022. Before I turn to our guidance for the year, let me add some color to the reporting changes that align with our new operating model Jim and Mark introduced this afternoon. For the reporting period beginning January 1, 2022, we will change our reportable segments to Healthcare, Education and Commercial, aligning the operating segments to be inclusive of all revenue and costs associated with each industry. This new reporting structure will result in some revenue and costs, historically reported in the Business Advisory segment, to now be reported in the Healthcare and Education Industry segments for engagements delivered in those industries. In addition, some revenues and costs historically reported in the Education segment will now be reported in the Healthcare Industry segment. We will also provide revenue reporting across our two principal capabilities: first, Consulting and Managed Services; and second, Digital. These changes will create greater transparency into the core drivers of the business across the company. As Jim mentioned, we have placed supplemental materials on the Investor Relations section of the Huron website to provide additional detail on our recap financial information, including unaudited summary financial information and other data according to our new reporting segments. Finally, let me turn to our expectations and guidance for 2022. For the full year 2022, we anticipate revenues before reimbursable expenses in a range of $970 million to $1.03 billion with a midpoint of $1 billion. Adjusted EBITDA in a range of 11.3% to 12.3% of revenues and adjusted non-GAAP EPS in the range of $2.85 to $3.35. We expect cash flows from operations to be in the range of $90 million to $110 million. Capital expenditures are expected to be approximately $20 million to $25 million, and free cash flows are expected to be in the range of $70 million to $90 million net of cash taxes and interest excluding non-cash stock compensation. Weighted average diluted share count for 2022 is expected to be 21.5 million. Finally, with respect to taxes, you should assume an effective tax rate in the range of 28% to 30%, which comprises the federal tax rate of 21%, a blended state tax rate of 5% to 6% and incremental tax expense related to certain nondeductible expense items. Let me add some color to our guidance starting with revenue. The midpoint of the revenue range reflects 10% of revenue growth over 2021 revenue of $906 million. The midpoint of guidance also assumes that the first quarter of 2022 revenues will increase at a mid-teens percentage level over the first quarter of 2021 with sequential growth thereafter as the year progresses. With regard to our new Healthcare Industry segment, which we will begin reporting in 2022, we expect high single-digit revenue growth for full year 2022, and we expect operating margins will be in the range of approximately 25% to 27%, inclusive of digital offerings that will now be reported within the segment. This compares to 26.6% for full year 2021 on a recast basis. In the new Education Industry segment, we expect mid to high-teen percentage revenue growth for the full year 2022, and we expect operating margins will be in a range of approximately 23% to 25%, inclusive of digital offerings that will now be reported within the segment. This compares to 21.6% for full year 2021 on a recast basis. In the new Commercial segment, we expect to see mid- to high single-digit percentage of revenue growth for 2022. We expect our operating margins in this segment to be in the range of 19% to 21%. This compares to 15.7% for full year 2021 on a recast basis. We expect unallocated corporate SG&A to increase on a mid- to upper single-digit percentage basis for full year 2022, compared to 2021 as we incur some incremental costs to support revenue growth as well as an anticipated return of some travel and meeting expenses. Turning to the total company, Huron’s adjusted EBITDA margin is expected to be in the range of 11.3% to 12.3% of revenues, an increase of 100 basis points at the midpoint of guidance compared to 2021. Also, in the first quarter, consistent with prior years, we note the following items as it relates to expenses: The reset of wage basis for FICA and our 401(k) match, our annual merit and promotion wage increases go into effect on January 1 and an increase in stock compensation expense for restricted stock awards that will be granted in March to retirement-eligible employees. Based on these factors, we anticipate approximately 10% to 15% of our full year adjusted EBITDA and full year adjusted EPS to be generated during the first quarter. As a closing reminder, with respect to 2021 adjusted EBITDA, adjusted net income and adjusted EPS, there are several items that you will need to consider when reconciling these non-GAAP measures to comparable GAAP measures. The reconciliation schedules that we included in our press release will help walk you through these reconciliations. Thanks everyone. I would now like to turn the call back over to Jim before we open the call to s. Jim?